252 related articles for article (PubMed ID: 28050800)
1. Micro-RNA-204 Participates in TMPRSS2/ERG Regulation and Androgen Receptor Reprogramming in Prostate Cancer.
Todorova K; Metodiev MV; Metodieva G; Mincheff M; Fernández N; Hayrabedyan S
Horm Cancer; 2017 Feb; 8(1):28-48. PubMed ID: 28050800
[TBL] [Abstract][Full Text] [Related]
2. miR-204 is dysregulated in metastatic prostate cancer in vitro.
Todorova K; Metodiev MV; Metodieva G; Zasheva D; Mincheff M; Hayrabedyan S
Mol Carcinog; 2016 Feb; 55(2):131-47. PubMed ID: 25630658
[TBL] [Abstract][Full Text] [Related]
3. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.
Hermans KG; van Marion R; van Dekken H; Jenster G; van Weerden WM; Trapman J
Cancer Res; 2006 Nov; 66(22):10658-63. PubMed ID: 17108102
[TBL] [Abstract][Full Text] [Related]
4. ERG signaling in prostate cancer is driven through PRMT5-dependent methylation of the Androgen Receptor.
Mounir Z; Korn JM; Westerling T; Lin F; Kirby CA; Schirle M; McAllister G; Hoffman G; Ramadan N; Hartung A; Feng Y; Kipp DR; Quinn C; Fodor M; Baird J; Schoumacher M; Meyer R; Deeds J; Buchwalter G; Stams T; Keen N; Sellers WR; Brown M; Pagliarini RA
Elife; 2016 May; 5():. PubMed ID: 27183006
[TBL] [Abstract][Full Text] [Related]
5. Binding of TMPRSS2-ERG to BAF Chromatin Remodeling Complexes Mediates Prostate Oncogenesis.
Sandoval GJ; Pulice JL; Pakula H; Schenone M; Takeda DY; Pop M; Boulay G; Williamson KE; McBride MJ; Pan J; St Pierre R; Hartman E; Garraway LA; Carr SA; Rivera MN; Li Z; Ronco L; Hahn WC; Kadoch C
Mol Cell; 2018 Aug; 71(4):554-566.e7. PubMed ID: 30078722
[TBL] [Abstract][Full Text] [Related]
6. [The progress of TMPRSS2-ETS gene fusions and their mechanism in prostate cancer].
Guo XQ; Gui YT; Cai ZM
Yi Chuan; 2011 Feb; 33(2):117-22. PubMed ID: 21377967
[TBL] [Abstract][Full Text] [Related]
7. Inactivation of AR/TMPRSS2-ERG/Wnt signaling networks attenuates the aggressive behavior of prostate cancer cells.
Li Y; Kong D; Wang Z; Ahmad A; Bao B; Padhye S; Sarkar FH
Cancer Prev Res (Phila); 2011 Sep; 4(9):1495-506. PubMed ID: 21680704
[TBL] [Abstract][Full Text] [Related]
8. Transcriptional network involving ERG and AR orchestrates Distal-less homeobox-1 mediated prostate cancer progression.
Goel S; Bhatia V; Kundu S; Biswas T; Carskadon S; Gupta N; Asim M; Morrissey C; Palanisamy N; Ateeq B
Nat Commun; 2021 Sep; 12(1):5325. PubMed ID: 34493733
[TBL] [Abstract][Full Text] [Related]
9. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming.
Iljin K; Wolf M; Edgren H; Gupta S; Kilpinen S; Skotheim RI; Peltola M; Smit F; Verhaegh G; Schalken J; Nees M; Kallioniemi O
Cancer Res; 2006 Nov; 66(21):10242-6. PubMed ID: 17079440
[TBL] [Abstract][Full Text] [Related]
10. Quantitative expression of TMPRSS2 transcript in prostate tumor cells reflects TMPRSS2-ERG fusion status.
Mwamukonda K; Chen Y; Ravindranath L; Furusato B; Hu Y; Sterbis J; Osborn D; Rosner I; Sesterhenn IA; McLeod DG; Srivastava S; Petrovics G
Prostate Cancer Prostatic Dis; 2010 Mar; 13(1):47-51. PubMed ID: 19597533
[TBL] [Abstract][Full Text] [Related]
11. Intratumoral androgen levels are linked to TMPRSS2-ERG fusion in prostate cancer.
Knuuttila M; Mehmood A; Mäki-Jouppila J; Ryberg H; Taimen P; Knaapila J; Ettala O; Boström PJ; Ohlsson C; Venäläinen MS; Laiho A; Elo LL; Sipilä P; Mäkelä SI; Poutanen M
Endocr Relat Cancer; 2018 Sep; 25(9):807-819. PubMed ID: 29773553
[TBL] [Abstract][Full Text] [Related]
12. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer.
Setlur SR; Mertz KD; Hoshida Y; Demichelis F; Lupien M; Perner S; Sboner A; Pawitan Y; Andrén O; Johnson LA; Tang J; Adami HO; Calza S; Chinnaiyan AM; Rhodes D; Tomlins S; Fall K; Mucci LA; Kantoff PW; Stampfer MJ; Andersson SO; Varenhorst E; Johansson JE; Brown M; Golub TR; Rubin MA
J Natl Cancer Inst; 2008 Jun; 100(11):815-25. PubMed ID: 18505969
[TBL] [Abstract][Full Text] [Related]
13. Relation of ETS transcription factor family member ERG, androgen receptor and topoisomerase 2β expression to TMPRSS2-ERG fusion status in prostate cancer.
Kolar Z; Burdova A; Jamaspishvili T; Bouchal J; Kucerova R; Bienova M; Kral M; Student V
Neoplasma; 2014; 61(1):9-16. PubMed ID: 24195515
[TBL] [Abstract][Full Text] [Related]
14. TMPRSS2:ERG blocks neuroendocrine and luminal cell differentiation to maintain prostate cancer proliferation.
Mounir Z; Lin F; Lin VG; Korn JM; Yu Y; Valdez R; Aina OH; Buchwalter G; Jaffe AB; Korpal M; Zhu P; Brown M; Cardiff RD; Rocnik JL; Yang Y; Pagliarini R
Oncogene; 2015 Jul; 34(29):3815-25. PubMed ID: 25263440
[TBL] [Abstract][Full Text] [Related]
15. TMPRSS2/ERG fusion gene expression alters chemo- and radio-responsiveness in cell culture models of androgen independent prostate cancer.
Swanson TA; Krueger SA; Galoforo S; Thibodeau BJ; Martinez AA; Wilson GD; Marples B
Prostate; 2011 Oct; 71(14):1548-58. PubMed ID: 21394739
[TBL] [Abstract][Full Text] [Related]
16. Significance of the TMPRSS2:ERG gene fusion in prostate cancer.
Wang Z; Wang Y; Zhang J; Hu Q; Zhi F; Zhang S; Mao D; Zhang Y; Liang H
Mol Med Rep; 2017 Oct; 16(4):5450-5458. PubMed ID: 28849022
[TBL] [Abstract][Full Text] [Related]
17. Genetic interaction between Tmprss2-ERG gene fusion and Nkx3.1-loss does not enhance prostate tumorigenesis in mouse models.
Linn DE; Bronson RT; Li Z
PLoS One; 2015; 10(3):e0120628. PubMed ID: 25780911
[TBL] [Abstract][Full Text] [Related]
18. Covid-19 pathogenesis in prostatic cancer and TMPRSS2-ERG regulatory genetic pathway.
Afshari A; Janfeshan S; Yaghobi R; Roozbeh J; Azarpira N
Infect Genet Evol; 2021 Mar; 88():104669. PubMed ID: 33301988
[TBL] [Abstract][Full Text] [Related]
19. Nuclear receptor ERRα and transcription factor ERG form a reciprocal loop in the regulation of TMPRSS2:ERG fusion gene in prostate cancer.
Xu Z; Wang Y; Xiao ZG; Zou C; Zhang X; Wang Z; Wu D; Yu S; Chan FL
Oncogene; 2018 Nov; 37(48):6259-6274. PubMed ID: 30042415
[TBL] [Abstract][Full Text] [Related]
20. 5' UTR control of native ERG and of Tmprss2:ERG variants activity in prostate cancer.
Zammarchi F; Boutsalis G; Cartegni L
PLoS One; 2013; 8(3):e49721. PubMed ID: 23472063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]